Primary objectives:~Part A: The primary objective of this Part is to demonstrate superiority of ensovibep, compared to placebo, in reducing SARS-CoV-2 viral load through Day 8.~Part B: The primary objective of this Part is to demonstrate superiority of ensovibep, compared to placebo, in reducing the occurrence of hospitalizations (≥ 24 hours of acute care) and/or emergency room visits related to COVID-19 or death from any cause up to Day 29.~Secondary objectives:~Part A: The secondary objectives of this Part are:~To assess the effect of ensovibep, compared to placebo, in reducing the occurrence of hospitalizations (≥ 24 hours of acute care) and/or emergency room visits related to COVID-19 or death from any cause up to Day 29~To assess the effect of ensovibep, compared to placebo, in reducing COVID-19 symptoms through Day 29~To evaluate safety and tolerability of ensovibep~To characterize the pharmacokinetics (PK) of ensovibep~Part B: The secondary objectives of this Part are:~To assess the effect of ensovibep, compared to placebo, in reducing SARS-CoV-2 viral load through Day 8~To assess the effect of ensovibep, compared to placebo, in reducing COVID-19 symptoms up to Day 29~To evaluate the immunogenicity of ensovibep during the study and its clinical relevance (PK, efficacy and safety)~To evaluate safety and tolerability of ensovibep~Although Amendment 2 was created, modifications for this amendment are not reflected as it was never approved or implemented in the US. The study was conducted under Global Protocol Amendment 1, the last active version of the protocol.
The purpose of this study is to establish the antiviral efficacy of ensovibep against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in humans, identify the optimal dose, and demonstrate its clinical value for treating COVID-19 in adult ambulatory patients.